Velpatasvir
Epclusa (velpatasvir) is a small molecule pharmaceutical. Velpatasvir was first approved as Epclusa on 2016-06-28. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Epclusa's patents are valid until 2034-01-30 (FDA).
| Trade Name | Epclusa |
|---|---|
| Common Name | Velpatasvir |
| Indication | chronic hepatitis c, hepatitis c |
| Drug Class | Antivirals: NS5A inhibitors |
